Seeking Alpha

Deutsche says Sarepta fair value could exceed $200 per share

  • Sarepta Therapeutics (SRPT +1.9%) may be up 100% YTD, but that doesn't mean it can't rally another 294% or so, Deutsche's Robyn Karnauskas thinks.
  • Karnauskas — whose price target is currently $71 — further highlights the apparent efficacy disparity between drisapersen and eteplirsen noting that patients taking eteplirsen saw "stabilization in 6MWD as early as 24 weeks [and remained] stable even at 96 weeks."
  • Here's the real kicker though: "We could see FV in $98-$125 range if we assume 100% probability to Eteplirsen and 80-100% market share in treated patients. If we assume 100% probability to their other exon program, we get to SRPT FV of $213/share." (emphasis added)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs